Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- Conditions
- Interventions
- Registration Number
- NCT02928224
- Lead Sponsor
- Pfizer
- Brief Summary
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a...
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 702
- Age ≥ 18 years at time of informed consent
- Histologically- or cytologically-confirmed CRC that is metastatic
- Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any time prior to Screening or by the central laboratory
- Progression of disease after 1 or 2 prior regimens in the metastatic setting
- Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1
- Adequate bone marrow, cardiac, kidney and liver function
- Able to take oral medications
- Female patients are either postmenopausal for at least 1 year, are surgically sterile for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy from screening through follow-up if of childbearing potential
- Males must agree to take appropriate precautions to avoid fathering a child from screening through follow-up
Key
- Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab, panitumumab or other epidermal growth factor receptor (EGFR) inhibitors
- Prior irinotecan hypersensitivity or toxicity that would suggest an inability to tolerate irinotecan 180 mg/m2 every 2 weeks
- Symptomatic brain metastasis or leptomeningeal disease
- History or current evidence of retinal vein occlusion or current risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes)
- Known history of acute or chronic pancreatitis
- History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months prior to randomization
- Uncontrolled blood pressure despite medical treatment
- Impaired GI function or disease that may significantly alter the absorption of encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption)
- Concurrent or previous other malignancy within 5 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or indolent malignancy
- History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli
- Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy)
- Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathy
- Known history of HIV infection
- Active hepatitis B or hepatitis C infection
- Known history of Gilbert's syndrome
- Known contraindication to receive cetuximab or irinotecan at the planned doses
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Safety Lead-in, Triplet Arm Binimetinib Encorafenib + binimetinib + cetuximab. Safety Lead-in, Triplet Arm Cetuximab Encorafenib + binimetinib + cetuximab. Doublet Arm Encorafenib Encorafenib + cetuximab. Doublet Arm Cetuximab Encorafenib + cetuximab. Control Arm Cetuximab Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Control Arm Irinotecan Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Control Arm Folinic Acid Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Control Arm 5-Fluorouracil Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Safety Lead-in, Triplet Arm Encorafenib Encorafenib + binimetinib + cetuximab.
- Primary Outcome Measures
Name Time Method (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs) Cycle 1 (up to 28 days) (Safety Lead-in) Number of Participants With Adverse Events (AEs) Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting AEs were reported in this outcome measure.
(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis Duration of safety lead-in, approximately 6 months (up to 28 days per cycle) An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.
(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks) An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants according to incidence of dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure.
(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm) OS was defined as the time from randomization to death due to any cause.
(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of complete response (CR) or partial response (PR), where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 millimeter \[mm\] short axis), and PR: at least ...
- Secondary Outcome Measures
Name Time Method (Safety Lead-in) Objective Response Rate (ORR) by Investigator From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Objective Response Rate (ORR) by BICR From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Safety Lead-in) Duration of Response (DOR) by Investigator From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks) DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression o...
(Safety Lead-in) Duration of Response (DOR) by BICR From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks) DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target ...
(Safety Lead-in) Time to Response by Investigator From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Safety Lead-in) Time to Response by BICR From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Safety Lead-in) Progression-Free Survival (PFS) by Investigator From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Safety Lead-in) Progression-Free Survival (PFS) by BICR From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 52.4 weeks for control arm) OS was defined as the time from randomization to death due to any cause.
(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 89.1 weeks for triplet arm) OS was defined as the time from randomization to death due to any cause.
(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Control Arm Per BICR From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per BICR From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm) PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more...
(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator Duration of Phase 3, approximately 6 months (up to 28 days per cycle) ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, ta...
(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm) DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target ...
(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm) DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression o...
(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm) DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target ...
(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm) DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target ...
(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm) DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target ...
(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm) DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target ...
(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm) Time to response was defined as the time from first dose to first radiographic evidence of response.
(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days) The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, \& social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, \& nausea \& vomiting); \& 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sle...
(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days) FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants \& participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional we...
Phase 3: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Clinically notable shifts was defined as worsening by at least 2 grades or to more than or equal to (\>=) Grade 3 based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death.
(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days) The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single ...
(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days) The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: "Since starting treatment, my colorectal cancer symptoms are...
(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Cetuximab Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Encorafenib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Binimetinib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve From Zero to the Last Measurable Time Point (AUClast) for Metabolite of Binimetinib (AR00426032) Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032) Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032) Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days) (Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days) The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to registe...
Phase 3: Number of Participants With Clinically Notable Shifts in Urinalysis Laboratory Parameters From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Clinically notable shifts was defined as worsening by at least 2 grades or to \>= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death.
Phase 3: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: low/high systolic blood pressure (SBP): \<= 90 millimeters of mercury (mmHg) with decrease from baseline of \>= 20mmHg or \>= 160mmHg with increase from baseline of \>= 20mmHg, low or high d...
Phase 3: Number of Participants With Newly Occurring Clinically Notable Electrocardiogram (ECG) Values From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: heart rate- decrease from baseline \> 25% and to a value \< 50 and increase from baseline \> 25% and to a value \> 100. QT interval- new \> 450 (millisecond) msec, new \> 480 msec, new \> 50...
(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days) The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to registe...
Phase 3: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Clinically notable shifts was defined as worsening by at least 2 grades or to \>= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death.
Phase 3: Number of Participants With Shift in Visual Acuity Logarithm of the Minimum Angle of Resolution (LogMAR) Score From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Visual acuity was measured using the Snellen visual acuity conversion chart. This was determined by establishing the smallest optotypes that could be identified correctly by the participant at a given observation distance. Snellen visual acuity was reported as a Snellen fraction (m/M) in which the numerator (m) indicated the test distance and the denominator...
(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days) The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to registe...
Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks) Left ventricular ejection fraction (LVEF) abnormalities were defined according to CTCAE version 4.03 where Grade 0: Non-missing value below Grade 2, Grade 2: LVEF between 40% and 50% or absolute change from baseline between -10% and \< -20%, Grade 3: LVEF between 20% and 39% or absolute change from baseline \<= -20%, Grade 4: LVEF lower than 20%. Categories ...
Trial Locations
- Locations (407)
The University of Kansas Cancer Center, Investigational Drug Services
🇺🇸Westwood, Kansas, United States
Hospital do Olho
🇧🇷Salvador, Bahia, Brazil
DZU, Diagnose Zentrum Urania GmbH
🇦🇹Wien, Austria
Medizinische Universitaet Wien/AKH Wien
🇦🇹Wien, Austria
Medizinische Universität Wien/AKH Wien
🇦🇹Wien, Austria
Pecsi Tudomanyegyetem Klinikai Kozpont
🇭🇺Pecs, Hungary
USC Eye Institute
🇺🇸Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
The Investigational Drug Pharmacy (IDS) in the Sidney Kimmel Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Ophthalmic Consultants of Boston Inc
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
The University of Texas MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
CENANTRON - Centro Avancado de Tratamento Oncologic
🇧🇷Belo Horizonte, Minas Gerais, Brazil
The University of Kansas Clinical Research Center
🇺🇸Fairway, Kansas, United States
ASST Bergamo Ovest, Ospedale Treviglio Caravaggio di Trevigl
🇮🇹Treviglio, Bergamo, Italy
KU Eye
🇺🇸Prairie Village, Kansas, United States
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
Odense University Hospital (OUH)
🇩🇰Odense C, Denmark
Mayo Clinic Hospital
🇺🇸Phoenix, Arizona, United States
Sylvester at Kendall
🇺🇸Miami, Florida, United States
Indiana University Health Melvin and Bren Simon Cancer Center
🇺🇸Indianapolis, Indiana, United States
Investigational Drug Services IUHSCC
🇺🇸Indianapolis, Indiana, United States
IU Health Springmill
🇺🇸Indianapolis, Indiana, United States
Oregon Health and Science University
🇺🇸Portland, Oregon, United States
Henry-Joyce Cancer Clinic
🇺🇸Nashville, Tennessee, United States
Farmacia AOU di Cagliari Presidio Duilio Casula Monserrato
🇮🇹Monserrato, Cagliari, Italy
U.O. Oculistica, Istituto Clinico HUMANITAS
🇮🇹Rozzano, Milano, Italy
SC Oncologia Medica 1, SS Oncologia Medica Gastroenterologica
🇮🇹Milano, MI, Italy
UO Farmaceutica, Gestione del Farmaco - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara
🇮🇹Pisa, Italy
UO Oncologia Medica 2 - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara
🇮🇹Pisa, Italy
Dr. Clayton Berger (opthalmology)
🇺🇸Fort Lauderdale, Florida, United States
LAC+USC Medical Center
🇺🇸Los Angeles, California, United States
Mehmet F. Hepgur, MD - Broward Health Medical Center
🇺🇸Fort Lauderdale, Florida, United States
Illinois CancerCare- Galesburg
🇺🇸Galesburg, Illinois, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Illinois Cancer Care, PC
🇺🇸Peoria, Illinois, United States
Illinois Eye Center
🇺🇸Peoria, Illinois, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Cleveland Clinic Taussig Cancer Institute
🇺🇸Cleveland, Ohio, United States
Vanderbilt Eye Institute
🇺🇸Nashville, Tennessee, United States
University of Wisconsin Clinical Science Center
🇺🇸Madison, Wisconsin, United States
Central Adelaide Local Health Network Inc. operating as Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Mater Misericordiae Limited
🇦🇺South Brisbane, Queensland, Australia
Centro Medico CAIPO (Centro para la Atención del paciente Oncológico)
🇦🇷San Miguel de Tucumán, Tucumán, Argentina
CLINICA PERGAMINO S.A. (Centro de Investigacion Pergamino S.A.)
🇦🇷Pergamino, Buenos Aires, Argentina
St Vincent's Hospital Sydney
🇦🇺Darlinghurst, NEW South Wales (nsw), Australia
Newcastle Eye Centre
🇦🇺Sydney, NEW South Wales (nsw), Australia
University Hospital Gasthuisberg (UZ Leuven)
🇧🇪Leuven, Belgium
Centre Hospitalier Universitaire (CHU) de Liege
🇧🇪Liege, Belgium
Peter MacCallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Klinikum Wels-Grieskirchen GmbH, Abteilung fuer Innere Medizin II
🇦🇹Wels, Oberoesterreich, Austria
Klinikum Wels-Grieskirchen GmbH, Institut fuer Nuklearmedizin
🇦🇹Wels, Oberoesterreich, Austria
Instituto Vizibelli
🇧🇷Belo Horizonte, Minas Gerais, Brazil
Karen Miyuki Kubokawa Shorer
🇧🇷Sorocaba, SP, Brazil
Instituto de Ensino e Pesquisa São Lucas
🇧🇷São Paulo, Brazil
Ocni ordinace Oftalpro s.r.o.
🇨🇿Brno, Czechia
CHU Morvan
🇫🇷BREST Cedex, France
ICM Val d'Aurelle
🇫🇷Montpellier Cedex 5, France
Augentagesklinik Maria-Hilf Krankenhaus
🇩🇪Moenchengladbach, Nordrhein-westfalen, Germany
HKS Kardiologische Praxis am Israelitischen Krankenhaus
🇩🇪Hamburg, Germany
Facharztzentrum Eppendorf
🇩🇪Hamburg, Germany
Universitaetsklinikum Hamburg Eppendorf, Zentrum fuer Radiologie und Endoskopie
🇩🇪Hamburg, Germany
Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
🇮🇱Jerusalem, Israel
Magyar Honvedseg Egeszsegugyi Kozpont
🇭🇺Budapest, Hungary
SC Farmacia Aziendale - ASST Cremona, Ospedale di Cremona
🇮🇹Cremona, CR, Italy
Tsukahara Eye Clinic
🇯🇵Yokohama, Kanagawa, Japan
Wojewodzki Szpital Zespolony, Oddzial Onkologiczny
🇵🇱Elblag, Poland
Hospital Universitari Parc Tauli
🇪🇸Sabadell, Barcelona, Spain
Hospital Universitario Son Espases
🇪🇸Palma de Mallorca, Baleares, Spain
Hospital Universitari Sant Joan de Reus
🇪🇸Reus, Tarragona, Spain
Hospital Quiron Salud Barcelona
🇪🇸Barcelona, Spain
Clinica Corachan
🇪🇸Barcelona, Spain
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
Hospital Universitario de Burgos
🇪🇸Burgos, Spain
Gabinete Radiologico Dr. Pita
🇪🇸Madrid, Spain
Hospital General Universitario de Valencia
🇪🇸Valencia, Spain
Izmir Medical Park Hospital - Medical Oncology
🇹🇷Izmir, Izmir, Karsiyaka, Turkey
Hospital Universitario Miguel Servet
🇪🇸Zaragoza, Spain
China Medical University Hospital
🇨🇳Taichung, Taiwan
Imperial College Healthcare NHS Trust, Hammersmith Hospital
🇬🇧London, United Kingdom
The Christie NHS Foundation Trust - Christie Hospital
🇬🇧Manchester, United Kingdom
Centre Ophtalmologique - Pole Vision - Clinique Val d'Ouest
🇫🇷Ecully, France
Sarah Cannon Research Institute UK
🇬🇧London, United Kingdom
Osaka University Hospital Laboratory for Clinical Investigation
🇯🇵Suita, Osaka, Japan
Lukaskrankenhaus Neuss; Zentrale Apotheke
🇩🇪Neuss, Nordrhein-westfalen, Germany
Augenarzt Praxis Dr. med. Petra Huelsmann
🇩🇪Worms, Rheinland-pfalz, Germany
Institut Catala d'Oncologia
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Nuestra Señora del Rosario
🇪🇸Madrid, Madrid, Communidad Delaware, Spain
Hospital Universitario Ramón y Cajal
🇪🇸Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Hospital HM Universitario Sanchinarro
🇪🇸Madrid, Spain
Evangelisches Waldkrankenhaus Spandau
🇩🇪Berlin, Germany
Marsden Eye Specialists
🇦🇺Parramatta, NEW South Wales (nsw), Australia
Flinders Medical Centre
🇦🇺Bedford Park, South Australia, Australia
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)
🇺🇸Aurora, Colorado, United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
🇺🇸Duarte, California, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Keck Hospital of USC - Norris Healthcare Center (HC3)
🇺🇸Los Angeles, California, United States
Keck Hospital of USC
🇺🇸Los Angeles, California, United States
Norris Healthcare Center 3 (HC3)
🇺🇸Los Angeles, California, United States
Harvard Eye Associates
🇺🇸Orange, California, United States
Rocky Mountain Lions Eye Institute
🇺🇸Aurora, Colorado, United States
University of Colorado Hospital Inpatient Pavillion'
🇺🇸Aurora, Colorado, United States
Temple Medical Center
🇺🇸New Haven, Connecticut, United States
University of Colorado Cancer Center - Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
Smilow Cancer Hospital at Yale - New Haven
🇺🇸New Haven, Connecticut, United States
Yale University, Yale Cancer Center
🇺🇸New Haven, Connecticut, United States
Smilow Cancer Hospital Care Center at North Haven
🇺🇸North Haven, Connecticut, United States
Broward Health Medical Center
🇺🇸Fort Lauderdale, Florida, United States
The Lennar Foundation Medical Center
🇺🇸Coral Gables, Florida, United States
Mayo Clinic Florida
🇺🇸Jacksonville, Florida, United States
Sylvester Comprehensive Cancer Center/UMHC
🇺🇸Miami, Florida, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
🇺🇸New Lenox, Illinois, United States
Illinois CancerCare- Ottawa
🇺🇸Ottawa, Illinois, United States
The University of Chicago Medicine Center for Advanced Care Orland Park
🇺🇸Orland Park, Illinois, United States
Carle Cancer Center
🇺🇸Urbana, Illinois, United States
Sidney &Lois Eskenazi Hospital
🇺🇸Indianapolis, Indiana, United States
The University of Kansas Hospital
🇺🇸Kansas City, Kansas, United States
Baptist Health Floyd Cancer Center
🇺🇸New Albany, Indiana, United States
The University of Kansas Cancer Center and Medical Pavilion
🇺🇸Westwood, Kansas, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Brigham & Women's Hospital
🇺🇸Boston, Massachusetts, United States
Siteman Cancer Center - West County
🇺🇸Creve Coeur, Missouri, United States
Dana-Farber Cancer Institute (DFCI)
🇺🇸Boston, Massachusetts, United States
Saint Louis University
🇺🇸Saint Louis, Missouri, United States
SSM Health Saint Louis University Hospital
🇺🇸Saint Louis, Missouri, United States
Washington University Infusion Center Pharmacy
🇺🇸Saint Louis, Missouri, United States
Siteman Cancer Center - St Peters
🇺🇸Saint Peters, Missouri, United States
Siteman Cancer Center - South County
🇺🇸Saint Louis, Missouri, United States
Memorial Sloan Kettering: Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Memorial Sloan Kettering: Commack
🇺🇸Commack, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Memorial Sloan Kettering: Rockefeller Outpatient Pavilion
🇺🇸New York, New York, United States
Gabrail Cancer Center Research
🇺🇸Canton, Ohio, United States
OHSU Center for Health and Healing
🇺🇸Portland, Oregon, United States
Casey Eye Institute-South Waterfront
🇺🇸Portland, Oregon, United States
OHSU Research Pharmacy Services
🇺🇸Portland, Oregon, United States
Scott & White Clinic - Temple Pavilion
🇺🇸Temple, Texas, United States
Medical Oncology Associates, PS DBA Summit Cancer Centers
🇺🇸Spokane, Washington, United States
Scott & White Medical Center - Temple
🇺🇸Temple, Texas, United States
Centro Medico INFINITO
🇦🇷Santa Rosa, LA Pampa, Argentina
Inland Imaging, LLC Holy Family Hospital
🇺🇸Spokane, Washington, United States
Clinica Universitaria Reina Fabiola
🇦🇷Cordoba, Argentina
Providence Holy Family Nuclear Medicine
🇺🇸Spokane, Washington, United States
Centro Oncologico Riojano Integral - CORI
🇦🇷La Rioja, Argentina
Monash Health Translation Precinct - Monash Health
🇦🇺Clayton, Victoria, Australia
Austin Health
🇦🇺Heidelberg, Victoria, Australia
Central Adelaide Local Health Network Inc. operating as The Queen Elizabeth Hospital
🇦🇺Woodville South, South Australia, Australia
Klinikum Wels - Grieskirchen GmbH, Abteilung fuer Innere Medizin IV
🇦🇹Wels, Oberoesterreich, Austria
Klinikum Wels-Grieskirchen GmbH, Institut fuer Radiologie I
🇦🇹Wels, Oberoesterreich, Austria
Centre Hospitalier de l'Ardenne - Site de Libramont
🇧🇪Libramont-Chevigny, Luxembourg, Belgium
Imelda Ziekenhuis
🇧🇪Bonheiden, Belgium
Grand Hopital de Charleroi (GHdC)
🇧🇪Charleroi, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
AZ Maria Middelares
🇧🇪Gent, Belgium
CHC Saint Joseph
🇧🇪Liege, Belgium
AZ Delta Roeselaere-Menen
🇧🇪Roeselaere, Belgium
Centre Hospitalier Regional (CHR) - Verviers
🇧🇪Verviers, Belgium
CEMES Centro Medico Especializado em Oftalmologia
🇧🇷Cachoeiro de Itapemirim, ES, Brazil
CENOB - Centro de Oncologia da Bahia SS Ltda / Oncovida
🇧🇷Salvador, Bahia, Brazil
Centro de Pesquisas Clínicas em Oncologia
🇧🇷Cachoeiro de Itapemirim, ES, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
🇧🇷Cachoeiro de Itapemirim, ES, Brazil
Daniel Lubisco Pandolfi
🇧🇷Lajeado, RS, Brazil
Sociedade Beneficencia e Cardade de Lajeado/Hospital Bruno Born
🇧🇷Lajeado, RS, Brazil
Consultorio Medico de Oftalmologia - Dr. Ricardo Tres
🇧🇷Passo Fundo, RS, Brazil
Hospital Sao Vicente de Paulo
🇧🇷Passo Fundo, RS, Brazil
Thiago Vernetti Ferreira
🇧🇷Pelotas, RS, Brazil
Leandro Becker
🇧🇷Pelotas, RS, Brazil
UPCO - Unidade de Pesquisas Clinicas em Oncologia
🇧🇷Pelotas, RS, Brazil
Fernanda Mendes
🇧🇷Pelotas, RS, Brazil
Diogo Duarte Torre
🇧🇷Porto Alegre, RS, Brazil
Fernanda Lauermann
🇧🇷Pelotas, RS, Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Farmacia Central da Irmandade da Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Clinica de Oftalmologia Lavinsky
🇧🇷Porto Alegre, RS, Brazil
Nucleo de Novos Tratamentos em Cancer
🇧🇷Porto Alegre, RS, Brazil
Clinica Toller
🇧🇷Barretos, SAO Paulo, Brazil
Centro de Pesquisa Clínica de Oncologia e Hematologia - Hospital Mãe de Deus/AESC
🇧🇷Porto Alegre, RS, Brazil
Fundacao Pio XII
🇧🇷Barretos, SAO Paulo, Brazil
Olhos Centro Diagnostico e Laser LTDA
🇧🇷Barretos, SAO Paulo, Brazil
FUNDAÇÃO DO ABC - Faculdade de Medicina do ABC
🇧🇷Santo Andre, SP, Brazil
Giuliano Santos Borges - ME / Clinica de Neoplasias Litoral - Centro de Novos Tratamentos Itajai
🇧🇷Itajai, SC, Brazil
CEPOS - Centro de Estudos e Pesquisas Oncologicas de Sorocaba
🇧🇷Sorocaba, SP, Brazil
Instituto de Oncologia de Sorocaba "Dr. Gilson Delgado"
🇧🇷Sorocaba, SP, Brazil
Oftalmologia Diagnostica de Sorocaba (ODS)
🇧🇷Sorocaba, SP, Brazil
Instituto de Ensino e Pesquisa São Lucas - Pharmacy
🇧🇷São Paulo, Brazil
Hospital Leforte
🇧🇷São Paulo, Brazil
BC Cancer, Vancouver Center
🇨🇦Vancouver, British Columbia, Canada
IPEPO - Instituto da Visao
🇧🇷São Paulo, Brazil
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Masarykuv onkologicky ustav
🇨🇿Brno, Czechia
Instituto Clinico Oncologico del Sur (ICOS)
🇨🇱Temuco, Region DE LA Araucania, Chile
Centre integre universitaire de sante et de services sociaux de l'Ouest-de-l'Ile-de-Montreal
🇨🇦Montreal, Quebec, Canada
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Fingerlanduv ustav patologie
🇨🇿Hradec Kralove, Czechia
I. interni kardioangiologicka klinika
🇨🇿Hradec Kralove, Czechia
Klinika nemoci koznich a pohlavnich
🇨🇿Hradec Kralove, Czechia
Nemocnicni lekarna - Usek klinickych studii
🇨🇿Hradec Kralove, Czechia
Ocni klinika
🇨🇿Hradec Kralove, Czechia
Soroka University Medical Center
🇮🇱Be'er-Sheva, Israel
Radiologicka klinika
🇨🇿Hradec Kralove, Czechia
Fakultni nemocnice Olomouc, I. interni klinika - kardiologicka
🇨🇿Olomouc, Czechia
Fakultni nemocnice Olomouc, Lekarna
🇨🇿Olomouc, Czechia
Hopital Jean Minjoz
🇫🇷Besancon Cedex, France
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
Centre Leon Berard
🇫🇷Lyon Cedex 08, France
CHU HOTEL-Dieu
🇫🇷Nantes Cedex, France
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
🇫🇷Paris Cedex 12, France
Hopital Georges Pompidou
🇫🇷Paris, France
Centre Hospitalier National d'Opthalmologie des Quinze-Vingts (CHNO des XV-XX)
🇫🇷Paris Cedex 12, France
CHU Robert Debre
🇫🇷Reims Cedex, France
SCM Centre d'ophtalmologie
🇫🇷Saint Jeand De Vedas, France
CHU Toulouse-Institut Inuversitaire du Cancer Toulouse
🇫🇷Toulouse Cedex 9, France
CHU Toulouse-Rangueil
🇫🇷Toulouse Cedex 9, France
CHU Toulouse - Purpan, hopital Pierre-Paul Riquet
🇫🇷Toulouse, France
Gustave Roussy
🇫🇷Villejuif Cedex, France
Universitaetsklinikum Ulm
🇩🇪Ulm, Baden-wuerttemberg, Germany
Universitaetsklinikum Tuebingen
🇩🇪Tuebingen, Baden-wuerttemberg, Germany
Augenklinik der Universitaet Muenchen
🇩🇪Muenchen, Bayern, Germany
LMU Klinikum der Universitaet Muenchen, Campus Grosshadern
🇩🇪Muenchen, Bayern, Germany
Medizinische Hochschule Hannover (MHH)
🇩🇪Hannover, Niedersachsen, Germany
Kliniken Essen Mitte / Knappschaftskrankenhaus
🇩🇪Essen, Nordrhein-westfalen, Germany
Kliniken Essen-Mitte
🇩🇪Essen, Nordrhein-westfalen, Germany
Praxis fuer Augenheilkunde Dr. Edmund Meyer-Schwickerath
🇩🇪Essen, Nordrhein-westfalen, Germany
Universitaetsklinikum Essen (AoeR), Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum
🇩🇪Essen, Nordrhein-westfalen, Germany
Universitaetsklinikum Essen; Diagnostischeu. Interventionelle Radiologie u. Neuroradiologie
🇩🇪Essen, Nordrhein-westfalen, Germany
Universitaetsklinikum Essen; Nuklearmedizin
🇩🇪Essen, Nordrhein-westfalen, Germany
Universitaetsklinikum Essen; Zentralapotheke
🇩🇪Essen, Nordrhein-westfalen, Germany
Evang. Krankenhaus Essen - Werden; Klinik fuer Augenheilkunde
🇩🇪Essen, Nordrhein-westfalen, Germany
Kliniken Maria Hilf GmbH - Franziskuskrankenhaus
🇩🇪Moenchengladbach, Nordrhein-westfalen, Germany
Kliniken Maria Hilf GmbH; Klinik fuer Radiologie
🇩🇪Moenchengladbach, Nordrhein-westfalen, Germany
Institut f. Pathologie - Ruhr-Universitaet Bochum, Prof. Dr. med. Andrea Tannapfel
🇩🇪Bochum, North Rhine Westfalia, Germany
Martin Apotheke
🇩🇪Worms, Rheinland-pfalz, Germany
Praxisgemeinschaft Kruse + Hofstaetter
🇩🇪Worms, Rheinland-pfalz, Germany
Onkologische Schwerpunktpraxis Worms
🇩🇪Worms, Rheinland-pfalz, Germany
Universitaetsklinikum Hamburg Eppendorf, Klinik fuer Augenheilkunde
🇩🇪Hamburg, Germany
Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden
🇩🇪Dresden, Germany
ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld
🇩🇪Hamburg, Germany
Radiologie im Israelitischen Krankenhaus
🇩🇪Hamburg, Germany
Zala Megyei Szent Rafael Korhaz - Onkologiai Osztaly
🇭🇺Zalaegerszeg, Zala, Hungary
Szent Margit Kórház
🇭🇺Budapest, Hungary
Eszak-Pesti Centrumkorhaz-Honvedkorhaz
🇭🇺Budapest, Hungary
Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet
🇭🇺Budapest, Hungary
Uzsoki Utcai Korhaz
🇭🇺Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar
🇭🇺Pecs, Hungary
The Barzilai Medical Center - Oncology Institute
🇮🇱Ashkelon, Israel
Tel Aviv Sourasky Medical Center - Oncology
🇮🇱Tel-Aviv, NAP, Israel
MOR Institute
🇮🇱Bnei Brak, Israel
Ein-Karem Department of Medical Imaging of Hadassah Medical Organization, Hadassah Medical Center,
🇮🇱Jerusalem, Israel
Pharmacy of Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem
🇮🇱Jerusalem, Israel
Mt. Scopus Department of Medical Imaging of Hadassah Medical Organization,
🇮🇱Jerusalem, Israel
Imaging Department of Meir Medical Center
🇮🇱Kfar Saba, Israel
Pharmacy of Rabin Medical Center, Beilinson Hospital
🇮🇱Petah Tikva, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center, Beilinson Hospital
🇮🇱Petah Tikva, Israel
The Chaim Sheba Medical Center
🇮🇱Tel-Hashomer, Israel
Ospedali Riuniti Umberto I
🇮🇹Torrette Di Ancona, Ancona, Italy
Oculistica, ASST Papa Giovanni XXIII
🇮🇹Bergamo, BG, Italy
Oncologia, ASST Papa Giovanni XXIII
🇮🇹Bergamo, BG, Italy
Clinica di Oncologia Medica AOU di Cagliari Presidio Duilio Casula Monserrato
🇮🇹Monserrato, Cagliari, Italy
Radiologia AOU di Cagliari Presidio Duilio Casula Monserrato
🇮🇹Monserrato, Cagliari, Italy
Oculistica - ASST Cremona, Ospedale di Cremona
🇮🇹Cremona, CR, Italy
U.O. di Oncologia ed Ematologia, Istituto Clinico HUMANITAS
🇮🇹Rozzano (MI), Milan, Italy
SC Oncologia - ASST Cremona, Ospedale di Cremona
🇮🇹Cremona, CR, Italy
IRCCS Ospedale San Raffaele - U.O. di Medicina Oncologica
🇮🇹Milano, MI, Italy
S.C. Radiologia diagnostica e interventistica - Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, MI, Italy
Servizio di Farmacia - IRCCS Ospedale San Raffaele
🇮🇹Milano, MI, Italy
Cardiologia per i pazienti oncologici - Istituto Oncologico Veneto I.R.C.C.S
🇮🇹Padova, PD, Italy
Clinica Oculistica - Azienda Ospedaliera di Padova
🇮🇹Padova, PD, Italy
Divisione Anatomia Patologica Presidio San Giovanni di Dio
🇮🇹Cagliari, Italy
Oculistica AOU di Cagliari Presidio San Giovanni di Dio
🇮🇹Cagliari, Italy
U.O. Oncologia Medica 1 - Istituto Oncologico Veneto I.R.C.C.S
🇮🇹Padova, PD, Italy
Policlinico S.Orsola Malpighi, AOU di Bologna - Oncologia Medica
🇮🇹Bologna, Italy
Dipartimento Neuromuscoloscheletrico e Organi di Senso, "Oncologia Oculare Unit"
🇮🇹Firenze, Italy
Radiologia
🇮🇹Milano, Italy
SC oncologia Medica I - Azienda Ospedaliero Universitaria Careggi
🇮🇹Firenze, Italy
Unita di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini
🇮🇹Milano, Italy
SSD Day Hospital Oncologico - Dipartimento ad attivita integrata di Oncologia, Ematologia
🇮🇹Modena, Italy
Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Dipartimento Interaziendale Farmaceutico - AOU Policlinico di Modena
🇮🇹Modena, Italy
SC di Oftalmologia - AOU Policlinico di Modena
🇮🇹Modena, Italy
SC di Radiologia, Dipartimento Interaziendale integrato Diagnostica per Immagini
🇮🇹Modena, Italy
AOU Universita degli Studi della Campania L. Vanvitelli - DAI di Medicina Interna e Specialistica
🇮🇹Napoli, Italy
AOU Universita degli Studi della Campania L. Vanvitelli - U. Ma.Ca.
🇮🇹Napoli, Italy
AOU Universita degli Studi della Campania L. Vanvitelli
🇮🇹Napoli, Italy
SOD Radiodiagnostica 3 - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara
🇮🇹Pisa, Italy
UO Oculistica - AOU Pisana, Stabilimento Ospedaliero di Cisanello
🇮🇹Pisa, Italy
U.O.S.D. Oncologia Medica, Dipartimento di Medicina - Fondazione PTV Policlinico Tor Vergata
🇮🇹Roma, Italy
U.O.S.D. Patologie Retiniche - Fondazione PTV Policlinico Tor Vergata
🇮🇹Roma, Italy
Chayagasaka Eye Clinic
🇯🇵Nagoya, Aichi, Japan
Aichi Cancer Center Hospital
🇯🇵Nagoya, Aichi, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa-shi, Chiba, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Ishikawa, Japan
St. Marianna University School of Medicine Hospital
🇯🇵Kawasaki, Kanagawa, Japan
Kanagawa Cancer Center
🇯🇵Yokohama, Kanagawa, Japan
Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers
🇯🇵Fukuoka, Japan
National Hospital Organization Osaka National Hospital
🇯🇵Osaka, Japan
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Gyeonggi-do, Korea, Republic of
Ajou University Hospital
🇰🇷Suwon, Gyeonggi-do, Korea, Republic of
Hallym University Sacred Heart Hospital
🇰🇷Anyang, Gyeonggido, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Korea University Anam Hospital IRB
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Superare Centro de Infusion S.A. de C.V.
🇲🇽Delegacion Cuauhtemoc, Ciudad DE Mexico, Mexico
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Rijnstate Hospital Arnhem
🇳🇱Arnhem, Gelderland, Netherlands
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Maastricht University Medical Center (MUMC)
🇳🇱Maastricht, Limburg, Netherlands
Rijnstate Hospital Velp
🇳🇱Velp, Gelderland, Netherlands
Haga Ziekenhuis
🇳🇱Den Haag, Zuid-holland, Netherlands
Onze Lieve Vrouwen Gasthuis
🇳🇱Amsterdam, Noord-holland, Netherlands
Colosseum Øyelegesenter C/O LB Holdings AS
🇳🇴Oslo, Norway
Sykehusapoteket Oslo, Radiumhospitalet
🇳🇴Oslo, Norway
Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina
🇵🇱Otwock, Poland
Oslo universitetssykehus, Radiumhospitalet
🇳🇴Oslo, Norway
Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
🇵🇱Brzozow, Poland
Szpital Specjalistyczny im. L. Rydygiera w Krakowie Sp.z.o.o.
🇵🇱Krakow, Poland
NZOZ Centrum Medyczne HCP
🇵🇱Poznan, Poland
NZOZ Przychodnia Specjalistyczna GUTMED
🇵🇱Poznan, Poland
MAGODENT Sp. z o.o. Szpital Elblaska
🇵🇱Warszawa, Poland
Regional Budgetary Healthcare Institution Kursk Regional Clinical
🇷🇺Kursk, Kursk Region, Russian Federation
Evimed Llc
🇷🇺Chelyabinsk, Russian Federation
Federal State Budget Institution "N.N. Blokhin Russian Cancer Research Center" of the
🇷🇺Moscow, Russian Federation
A. Tsyb Medical Radiological Research Center - branch of the
🇷🇺Obninsk, Russian Federation
Federal State Budget Institution "N.N. Blokhin Russian Cancer Research Center"
🇷🇺Moscow, Russian Federation
Sercosa - Clinica de las Nieves
🇪🇸Jaen, Andalucia, Spain
Complejo Hospitalario de Jaen
🇪🇸Jaen, Andalucia, Spain
Hospital Universitario Reina Sofía
🇪🇸Cordoba, Cordona, Spain
State Budgetary Educational Institution of Higher Professional Education First Saint Petersburg
🇷🇺Sankt-Petersburg, Russian Federation
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Universitario Vall d'Hebron
🇪🇸Barcelona, Spain
Cetir Centre Medic S.L.
🇪🇸Barcelona, Spain
Consulta Dr. Juan Carlos Castillo Dominguez
🇪🇸Cordoba, Spain
Fundacion Instituto Valenciano de Oncologia
🇪🇸Valencia, Spain
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Clinica Oftalvist
🇪🇸Valencia, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Uludag University Hospital
🇹🇷Bursa, Turkey
Hospital Quiron Salud Zaragoza
🇪🇸Zaragoza, Spain
Changhua Christian Hospital
🇨🇳Changhua city, Changhua County, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Chang Gung Memorial Hospital, Linkou
🇨🇳Taoyuan city, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Ege University Medical Faculty
🇹🇷Izmir, Bornova, Turkey
Medeniyet University Goztepe Training and Research Hospital
🇹🇷Istanbul, Kadikoy, Turkey
Hacettepe University Medical Faculty
🇹🇷Ankara, Turkey
Trakya Universitesi Tip Fakultesi
🇹🇷Edirne, Turkey
Inonu Universitesi Turgut Ozal Medical Center
🇹🇷Malatya, Turkey
Oftalmolohycheskyi tsentr "Vzghliad" MTs
🇺🇦Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine
Komumalnyi zaklad, Dnipropetrovska miska bahatoprofilna klinichna likarnia Nº4
🇺🇦Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine
Natsionalnyi medychnyi universytet imeni O.O Bohomltsia, kafedra oftalmolohii
🇺🇦Kyiv, Kyivska Oblast, Ukraine
Kyivska klinichna likarnia na zaliznychnomu transporti No3 filii Tsentr okhorony zdorov'ia PAT
🇺🇦Kyiv, Kyivska Oblast', Ukraine
Natsionalnyi medychnyi universytet imeni O.O Bohomltsia, kafedra onkolohii
🇺🇦Kyiv, Kyivska Oblast', Ukraine
Kyivskyi miskyi klinichnyi onkotsentr
🇺🇦Kyiv, Kyivska Oblast, Ukraine
Vinnytskyi oblasnyi klinichnyi onkolohichnyi dyspanser, viddilennia khimioterapii
🇺🇦Vinnytsia, Vinnyts'ka Oblast', Ukraine
Oleksandrivska klinichna likarnia mista Kyieva
🇺🇦Kyiv, Kyivska Oblast, Ukraine
TOV "Zakarpatskyi Tsentr Mikrokhirurhii Oka"
🇺🇦Uzhhorod, Zakarpatska Oblast, Ukraine
Tsentralna miska klinichna likarnia, Miskyi onkolohichnyi tsentr
🇺🇦Uzhgorod, Zakarpats'ka Oblast', Ukraine
NHS Grampian - Aberdeen Royal Infirmary
🇬🇧Aberdeen, Aberdeenshire Scotland, United Kingdom
King Edward V11 Hospital
🇬🇧Windsor, Berkshire, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧Glasglow, Glasglow City, Scotland, United Kingdom
University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital
🇬🇧Birmingham, WEST Midlands, United Kingdom
Hammersmith Hospital, Imperial College Healthcare NHS Trust
🇬🇧London, United Kingdom
Imperial College Healthcare NHS Trust, Charing Cross Hospital
🇬🇧London, United Kingdom
Hoag Memorial Hospital Presbyterian
🇺🇸Newport Beach, California, United States
Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc.
🇺🇸Fountain Valley, California, United States
University of Colorado Denver CTO (CTRC)
🇺🇸Aurora, Colorado, United States
Spokane Eye Clinic
🇺🇸Spokane, Washington, United States
Illinois CancerCare- Bloomington
🇺🇸Bloomington, Illinois, United States
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Mãe de Deus
🇧🇷Porto Alegre, RS, Brazil
Indiana University Health Hospital
🇺🇸Indianapolis, Indiana, United States
St Vincent's Clinic
🇦🇺Darlinghurst, NEW South Wales (nsw), Australia
Barnes Jewish Hospital
🇺🇸Saint Louis, Missouri, United States
Fundação Universidade de Caxias do Sul
🇧🇷Caxias do Sul, RS, Brazil
Medizinische Hochschule Hannover
🇩🇪Hannover, Niedersachsen, Germany
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Sunnybrook Research Institute
🇨🇦Toronto, Ontario, Canada
Associacao Hospitalar Beneficente Sao Vicente de Paulo / Hospital Sao Vicente de Paulo
🇧🇷Passo Fundo, RS, Brazil
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
🇧🇷Sao Jose do Rio Preto, SP, Brazil
Gemeinschaftspraxis fuer Radiologie und Nuklearmedizin, Standort Worms
🇩🇪Worms, Rheinland-pfalz, Germany
Chonnam National University Hwasun Hospital
🇰🇷Hwasun-gun, Jeollanam-do, Korea, Republic of
Klinikum Wels-Grieskirchen GmbH, Abteilung fuer Augenheilkunde und Optometrie
🇦🇹Wels, Oberoesterreich, Austria
AKH Wien
🇦🇹Wien, Austria
AZ Sint-Jan Brugge - Oostende AV - Campus Sint-Jan - Oncology
🇧🇪Brugge, WEST Vlaanderen, Belgium
Hospital Clinico Vina Del Mar
🇨🇱Vina del Mar, V Region Valparaiso, Chile
Augenarzt-Gemeinschaftspraxis Dr.med.Andreas Kind & Dr.med. Ute Kariger-Schweigert
🇩🇪Falkensee, Brandenburg, Germany
National Cancer Center Hospital
🇯🇵Chuo-ku, Tokyo, Japan
Consultorio dentro de la Torre Medica Dalinde (Oncologia Medica)
🇲🇽Ciudad de Mexico, Cuauhtemoc, Mexico
The Netherlands Cancer Institute
🇳🇱Amsterdam, Noord-holland, Netherlands
Universitair Medisch Centrum Utrecht
🇳🇱Utrecht, Netherlands
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
DVNZ "Uzhhorodskyi natsionalnyi universytet"
🇺🇦Uzhhorod, Zakarpatska Oblast, Ukraine
Derzhavnyi zaklad, Dnipropetrovska medychna akademiia Ministerstva okhorony zdorovia Ukrainy
🇺🇦Dnipropetrovsk, Dnipropetrovska Oblast', Ukraine
Eye Care Centre, Vancouver General Hospital
🇨🇦Vancouver, British Columbia, Canada
Related News
Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC - OncLive
- Prev
- 1
- Next